Wyeth subpoenaed on Protonix promos; Watson recalls Fentanyl patches;

> U.S. prosecutors have sent subpoenas to Wyeth seeking information on the drugmaker's promotion and pricing of the ulcer drug Protonix. Report

> Watson Pharmaceuticals is recalling one lot of its Fentanyl patches because some products are leaking fentanyl gel, which could cause an overdose for patients or caregivers; no injuries have yet been reported, however. Report

> More than 500 hospitals have enrolled in the risk-management program for Entereg, jointly marketed by GlaxoSmithKline and Adolor, since the post-op bowel drug was approved in June. Report

> Aurobindo Pharma said that it has received FDA approval for its Cefazolin injection, the generic version of Abraxis Pharmaceuticals' Cefazolin antibiotic. Report

> Treatment with the ovarian stimulant clomifene citrate--sold under a variety of brand names, including Clomid--works no better than placebo for couples with unexplained infertility problems. Report

> Dow Jones has crunched the numbers on the FDA's approval record this year, calculating that the nine new medicines OK'd for marketing in the first half of the year puts the agency on track to match last year's dismal record of 18 approvals. Report

> Sanofi-Aventis took a significant step forward in its effort to win an FDA approval for Multaq as a therapy for irregular heartbeat. Report

> Howard Richman, the former chief of regulatory affairs for Biopure, agreed to pay a $150,000 fine to settle federal charges that he had helped mislead investors in the company over the prospects of the blood substitute Hemopure at the FDA. Report

> San Diego-based Metabasis Therapeutics is getting a $10 million upfront injection from Roche to put its drug technology to work to find a new therapy for hepatitis C virus. Report

Emerging Drug Developer: Tetraphase Pharmaceuticals

And Finally... Could maggots offer the super solution to that pesky MRSA superbug? Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.